Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon.
Methods: Medline and Embase databases were search to identify eligible studies. Studies reporting use of botulinum toxin, effectiveness measures and safety outcomes were included.
Results: A total of 421 patients with Raynaud’s were identified of which 324 (77%) were determined to have a secondary cause. A total of 202 subjects had systemic sclerosis (SSc) (33% limited SSc, 22% diffuse SSc, and 45% unknown subtype). Botulinum toxin A doses ranged from 10-200 units, administered with similar frequency to the palm (n=272) and digits (n=253). The mean duration of benefit was 6.28 months with a range of 1 month to 8.6 years. There were no attributable deaths reported with botulinum toxin use. The most common adverse event was intrinsic muscle weakness (32 total events, frequency of 7.6%), and pain in 2 subjects. Only a single subject experienced persistent muscle weakness and atrophy. Benefit was consistently demonstrated across a heterogeneous group of objective and subjective outcomes.
Conclusion: Botulinum toxin injection for the management of refractory primary and secondary Raynaud’s phenomenon, using various doses and injection techniques, was demonstrated to be generally safe. Effectiveness of this treatment is suggested by the consistently positive, although heterogeneous, objective and subjective outcomes. These findings support the ongoing study of botulinum toxin for the management of refractory Raynaud’s phenomenon.
To cite this abstract in AMA style:Ennis D, Ahmad Z, Devakandan K, Anderson MA, Johnson S. Botulinum Toxin in the Management of Raynaud’s Phenomenon [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/botulinum-toxin-in-the-management-of-raynauds-phenomenon/. Accessed December 11, 2019.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/botulinum-toxin-in-the-management-of-raynauds-phenomenon/